Inmune Bio Files 8-K on Financials
Ticker: INMB · Form: 8-K · Filed: Nov 1, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Nov 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: INMB
TL;DR
INMB filed an 8-K on Oct 31, 2024, updating financials. Check it out.
AI Summary
Inmune Bio, Inc. filed an 8-K on November 1, 2024, reporting on its results of operations and financial condition as of October 31, 2024. The filing details the company's financial statements and exhibits, providing an update on its operational status.
Why It Matters
This filing provides investors with an update on Inmune Bio's financial health and operational results, which is crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate new material events or significant changes indicated.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- October 31, 2024 (date) — Date of earliest event reported
- November 1, 2024 (date) — Filing date
- 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 (address) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on the 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
What is the reporting period for the financial information?
The 'Conformed Period of Report' is October 31, 2024, and the 'Date of earliest event reported' is October 31, 2024.
When was this 8-K filing submitted to the SEC?
The filing was submitted on November 1, 2024.
What is Inmune Bio, Inc.'s principal executive office address?
The principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-11-01 16:23:48
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share INMB The NASDAQ Stock Mar
Filing Documents
- ea0219289-8k_inmune.htm (8-K) — 24KB
- ea021928902ex99-1_inmune.htm (EX-99.1) — 99KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-093531.txt ( ) — 315KB
- inmb-20241031.xsd (EX-101.SCH) — 3KB
- inmb-20241031_lab.xml (EX-101.LAB) — 33KB
- inmb-20241031_pre.xml (EX-101.PRE) — 22KB
- ea0219289-8k_inmune_htm.xml (XML) — 4KB
02 Results
Item 2.02 Results of Operations and Financial Condition. On October 31, 2024, INmune Bio Inc. issued a press release announcing its financial results and to provide a business update for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release of INmune Bio Inc., dated October 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: November 1, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2